- Home
- FBIO vs IMA Comparison
FBIO vs IMA Comparison
Compare FBIO & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- IMA
- Stock Information
- Founded
- FBIO 2006
- IMA 2019
- Country
- FBIO United States
- IMA United States
- Employees
- FBIO N/A
- IMA N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBIO Health Care
- IMA Health Care
- Exchange
- FBIO Nasdaq
- IMA Nasdaq
- Market Cap
- FBIO 88.7M
- IMA 92.2M
- IPO Year
- FBIO N/A
- IMA N/A
- Fundamental
- Price
- FBIO $2.56
- IMA $8.70
- Analyst Decision
- FBIO Strong Buy
- IMA Buy
- Analyst Count
- FBIO 2
- IMA 1
- Target Price
- FBIO $16.50
- IMA $30.00
- AVG Volume (30 Days)
- FBIO 1.0M
- IMA 99.7K
- Earning Date
- FBIO 11-13-2025
- IMA 11-15-2025
- Dividend Yield
- FBIO N/A
- IMA N/A
- EPS Growth
- FBIO N/A
- IMA N/A
- EPS
- FBIO N/A
- IMA N/A
- Revenue
- FBIO $59,301,000.00
- IMA $4,300,000.00
- Revenue This Year
- FBIO $31.85
- IMA N/A
- Revenue Next Year
- FBIO $44.43
- IMA N/A
- P/E Ratio
- FBIO N/A
- IMA N/A
- Revenue Growth
- FBIO N/A
- IMA N/A
- 52 Week Low
- FBIO $1.33
- IMA $7.24
- 52 Week High
- FBIO $4.20
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- FBIO 38.92
- IMA N/A
- Support Level
- FBIO $2.47
- IMA N/A
- Resistance Level
- FBIO $2.61
- IMA N/A
- Average True Range (ATR)
- FBIO 0.14
- IMA 0.00
- MACD
- FBIO -0.05
- IMA 0.00
- Stochastic Oscillator
- FBIO 20.93
- IMA 0.00
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.